US · JNJ
Johnson & Johnson
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- New Brunswick, NJ 08933
- Website
- jnj.com
Price · as of 2025-12-28
$227.19
Market cap 598.69B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $194.52 | -14.38% |
| Intrinsic Value(DCF) | $128.78 | -43.32% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $153.08 | -32.62% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.00 | $47.88 | |||
| 2012 | $0.00 | $44.46 | |||
| 2013 | $3.94 | $68.01 | |||
| 2014 | $4.68 | $71.24 | |||
| 2015 | $1.44 | $14.44 | |||
| 2016 | $0.37 | $64.89 | |||
| 2017 | $0.00 | $6.91 | |||
| 2018 | $0.00 | $84.09 | |||
| 2019 | $0.00 | $49.99 | |||
| 2020 | |||||
| 2021 | $0.00 | $48.65 | |||
| 2022 | $0.00 | $29.62 | |||
| 2023 | $0.00 | $66.32 | |||
| 2024 | $162.17 | $136.80 | $30.08 | $0.00 | $72.10 |
| 2025 | $248.56 | $194.52 | $36.06 | $0.00 | $153.08 |
AI valuation
Our deep-learning model estimates Johnson & Johnson's (JNJ) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $194.52
- Current price
- $227.19
- AI upside
- -14.38%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$128.78
-43.32% upside
Graham-Dodd
—
— upside
Graham Formula
$153.08
-32.62% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| JNJ | Johnson & Johnson | $227.19 | 598.69B | -14% | -43% | — | -33% | 22.52 | 7.40 | 6.41 | 15.83 | 24.88 | -34.24 | 72.78% | 27.17% | 28.46% | 35.03% | 21.82% | 14.13% | 0.59 | 26.36 | 1.03 | 0.69 | 0.71 | 9050.00% | 605.00% | -73.00% | 3.26% | 0.45 | 20.41% | 2.05% | 46.20% | 3.04% | 24.67 | 32.06 | 6.70 | 5.17 |
| ABBV | AbbVie Inc. | $232.03 | 410.27B | -31% | -54% | — | -83% | 99.26 | -128.28 | 6.86 | 17.08 | — | -4.58 | 83.71% | 34.69% | 6.91% | 15367.27% | 21.58% | 3.14% | -21.12 | 8.08 | 0.67 | 0.41 | 2.26 | -126.00% | 857.00% | -9.00% | 4.25% | 0.44 | 28.25% | 2.78% | 275.80% | 3.01% | 22.78 | 27.13 | 7.90 | 2.52 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| AZN | AstraZeneca PLC | $208.45 | 646.31B | -44% | -57% | -100% | -74% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVO | Novo Nordisk A/S | $37.45 | 166.46B | +59% | +7% | — | -3% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| UNH | UnitedHealth Group Incorp… | $293.27 | 265.66B | -28% | +144% | -84% | -12% | 20.96 | 2.68 | 0.60 | 13.82 | — | 2.68 | 18.53% | 4.24% | 2.69% | 13.29% | 11.37% | 4.21% | 0.78 | 4.74 | 0.79 | 0.45 | 2.18 | -1470.00% | 1181.00% | -2236.00% | 5.99% | 0.17 | 11.06% | 2.95% | 61.80% | 5.51% | 16.80 | 19.82 | 0.71 | 2.33 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
- CEO
- Joaquin Duato
- Employees
- 138.1K
- Beta
- 0.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($128.78 ÷ $227.19) − 1 = -43.32% (DCF, example).